Labianca R, Pancera G, Cesana B, Clerici M, Montinari F, Luporini G
Medical Oncology Department, S. Carlo Borromeo Hospital, Milan, Italy.
Eur J Cancer Clin Oncol. 1988 Oct;24(10):1579-81. doi: 10.1016/0277-5379(88)90048-x.
Sixty patients with advanced colorectal cancer were randomized between cisplatin (60 mg/mq i.v. every 3 weeks) + 5-fluorouracil (600 mg/mq i.v. bolus/weekly) and 5-fluorouracil alone (same schedule). In the 54 evaluable patients, no CR was observed. PR rate was 19.2% for the combination, and 14.5% for the monochemotherapy. Also the overall median survival time was similar for the two arms (10 and 13 months, respectively). Toxicity was acceptable, with more side-effects in the combination arm. Both treatments are of limited activity in advanced colorectal cancer and no advantage comes out from the use of this polychemotherapy.
60例晚期结直肠癌患者被随机分为顺铂（60mg/m²静脉注射，每3周一次）+5-氟尿嘧啶（600mg/m²静脉推注/每周一次）组和单纯5-氟尿嘧啶（相同方案）组。在54例可评估患者中，未观察到完全缓解（CR）。联合治疗组的部分缓解（PR）率为19.2%，单药化疗组为14.5%。此外，两组的总中位生存时间相似（分别为10个月和13个月）。毒性是可接受的，联合治疗组的副作用更多。两种治疗方法在晚期结直肠癌中的活性都有限，使用这种联合化疗并没有优势。
